Biostar Pharmaceuticals, Inc.
BSPM · OTC
12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |
|---|---|---|---|---|
| Revenue | $2,384 | $27,130 | $61,417 | $52,729 |
| % Growth | -91.2% | -55.8% | 16.5% | – |
| Cost of Goods Sold | $1,469 | $16,026 | $31,140 | $27,046 |
| Gross Profit | $915 | $11,104 | $30,276 | $25,683 |
| % Margin | 38.4% | 40.9% | 49.3% | 48.7% |
| R&D Expenses | $1,144 | $4,021 | $2,766 | $3,229 |
| G&A Expenses | $2,431 | $4,649 | $7,718 | $6,092 |
| SG&A Expenses | $3,601 | $13,288 | $26,205 | $22,667 |
| Sales & Mktg Exp. | $1,169 | $8,639 | $18,487 | $16,575 |
| Other Operating Expenses | -$265 | $4,667 | $2,618 | -$721 |
| Operating Expenses | $4,479 | $34,862 | $31,589 | $24,605 |
| Operating Income | -$3,564 | -$23,758 | -$1,313 | $508 |
| % Margin | -149.5% | -87.6% | -2.1% | 1% |
| Other Income/Exp. Net | $519 | -$35 | $2,847 | $231 |
| Pre-Tax Income | -$3,045 | -$23,793 | $1,535 | $2,656 |
| Tax Expense | $2,653 | $1,320 | -$3,314 | $1,847 |
| Net Income | -$5,698 | -$25,113 | $4,848 | $809 |
| % Margin | -239% | -92.6% | 7.9% | 1.5% |
| EPS | -2.5 | -11.36 | 2.3 | 0.49 |
| % Growth | 78% | -593.9% | 369.4% | – |
| EPS Diluted | -2.5 | -11.36 | 2.3 | 0.49 |
| Weighted Avg Shares Out | 2,297 | 2,211 | 2,071 | 1,644 |
| Weighted Avg Shares Out Dil | 2,297 | 2,211 | 2,071 | 1,644 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $9 | $1,330 | $1,345 |
| Interest Expense | $206 | $284 | $155 | $367 |
| Depreciation & Amortization | $1,143 | $2,320 | $3,086 | $2,787 |
| EBITDA | -$1,697 | -$21,189 | $4,775 | $5,810 |
| % Margin | -71.2% | -78.1% | 7.8% | 11% |